Sartorius and RoosterBio partner to advance scale-up of hMSC manufacturing
The collaboration aims to accelerate the development and commercialization of groundbreaking cell-based regenerative cures
Sartorius and RoosterBio — a supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks, highly engineered media and hMSC bioprocess systems — have agreed a strategic partnership aimed at advancing cell and gene therapy manufacturing.
The collaboration will focus on advancing the scale-up of hMSC manufacturing for regenerative medicine to significantly reduce process development efforts, industrialize the supply chain, and accelerate the development and commercialization of groundbreaking cell-based regenerative cures.
RoosterBio and Sartorius will create a set of Good Manufacturing Practice-compatible, customer-centric protocols using RoosterBio’s hMSC and media systems, alongside Sartorius’s single-use manufacturing technologies, process control software and cell analysis tools of hMSC final product manufacturing.
Cell expansion will be rapidly optimized using Sartorius’s benchtop Ambr system and MODDE design of experiment software allowing the technical team to compare cultures in identically sized, multi-parallel bioreactors to gain process information and optimized conditions in a short timeline.
The company's scalable Biostat STR production bioreactors will then be used to scale up to 50 L as part of this collaboration, with the system benefitting from scalability to 2000 L. Sartorius equipment will also be used to develop post-harvest processing methods with the kSep system as well as process and quality analytics.
According to the companies, this joint effort will simplify multiple steps in therapeutic development by providing robust, streamlined, end-to-end platform technologies and protocols that can be implemented for rapid scale-up of manufacturing processes, allowing product developers to significantly speed up their development timelines.
“Taking hMSC manufacturing to the thousand-liter scale is critical in meeting product dose requirements in commercial manufacturing,” said RoosterBio CEO Margot Connor.
Commenting further on the collaboration, she described the companies as "well-positioned to accomplish the clinical scale requirements of regenerative medicine product developers while laying the foundation for true commercial-scale manufacturing".
Both companies aim to use the data from this collaboration to provide co-learning and development opportunities to support the growing cell and gene therapy industry.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance